Who are Chidamide+ Fulvestrant's main competitors?

No direct comparators detected in our index.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/chidamide-fulvestrant.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Chidamide+ Fulvestrant — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Chidamide+ Fulvestrant (Chidamide+ Fulvestrant) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: HDAC inhibitor + selective estrogen receptor degrader (combination therapy). Area: Oncology.

marketed HDAC inhibitor + selective estrogen receptor degrader (combination therapy) Histone deacetylases (HDAC) + Estrogen receptor alpha (ERα) Oncology Small molecule Live · refreshed every 30 min

Target snapshot

Chidamide+ Fulvestrant (Chidamide+ Fulvestrant) — Liaoning Cancer Hospital & Institute. Chidamide inhibits histone deacetylases to reactivate tumor suppressor genes, while fulvestrant blocks estrogen receptor signaling to inhibit hormone-dependent breast cancer growth.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Chidamide+ Fulvestrant TARGET	Chidamide+ Fulvestrant	Liaoning Cancer Hospital & Institute	marketed	HDAC inhibitor + selective estrogen receptor degrader (combination therapy)	Histone deacetylases (HDAC) + Estrogen receptor alpha (ERα)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (HDAC inhibitor + selective estrogen receptor degrader (combination therapy) class)

Liaoning Cancer Hospital & Institute · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Chidamide+ Fulvestrant — Competitive Intelligence Brief. https://druglandscape.com/ci/chidamide-fulvestrant. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing